First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve

被引:154
|
作者
Rodriguez-Grunert, Leonardo [1 ]
Neto, Manoel Passos Galvao [2 ]
Alamo, Munir [1 ]
Ramos, Almino Cardoso [2 ]
Baez, Percy Brante [1 ]
Tarnoff, Michael [3 ]
机构
[1] Hosp Dipreca, Ctr Cirugia Obesidad, Santiago, Chile
[2] Gastro Obeso Ctr, Sao Paulo, Brazil
[3] Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA
关键词
Bariatric; Endoluminal; Diabetes; Obesity; Duodenum;
D O I
10.1016/j.soard.2007.07.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital. Methods: The DJBS is a 60-cm sleeve anchored in the duodenum to create a duodenal-jejunal bypass. In a 12-patient prospective, open-label, single-center, 12-week study, the device was endoscopically implanted, left in situ, and retrieved. The study included 5 men and 7 women, with a mean body mass index of 43 kg/m(2). Of the 12 patients, 4 had type 2 diabetes. The primary endpoints were the incidence and severity of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in co-morbid status. Results: The DJBS was endoscopically delivered and retrieved in all patients (mean implant/explant time of 26.6 and 43.3 min, respectively). Of the 12 patients, 10 were able to maintain the device for 12 weeks and 2 underwent explantation after 9 days secondary to poor device placement. Several self-limited adverse events were possibly or definitely related to the device, including 6 episodes of abdominal pain, 18 of nausea, and 16 of vomiting, mainly within 2 weeks of implantation. Two partial pharyngeal tears occurred during explantation. Implant site inflammation was encountered in all patients. No device-related event was considered severe. The average percentage of excess weight loss for the 10 patients with the device in place for 12 weeks was 23.6%, with all patients achieving at least 10% excess weight loss. All 4 diabetic patients had normal fasting plasma glucose levels without hypoglycemic medication for the entire 12 weeks. Of these 4 patients, 3 had decreased hemoglobin A(1C) of >=.5% by week 12. Conclusion: The DJBS can be safely delivered and removed endoscopically and left in situ for 12 weeks. The device had a favorable safety and encouraging efficacy profile. Randomized prospective trials are warranted. (Surg Obes Relat Dis 2008;4:55-59.) (C) 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [31] Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?
    Leventi, Eleni
    Guenthert, Sarah J.
    Stier, Christine
    Staikov, Plamen
    Stein, Juergen
    Farrag, Karima
    OBESITY SURGERY, 2019, 29 (05) : 1690 - 1693
  • [32] Duodenal-jejunal bypass changes the composition of the gut microbiota
    Hideya Kashihara
    Mitsuo Shimada
    Kozo Yoshikawa
    Jun Higashijima
    Toshihiro Nakao
    Masaaki Nishi
    Chie Takasu
    Surgery Today, 2017, 47 : 137 - 140
  • [33] THE DUODENAL-JEJUNAL BYPASS SLEEVE (ENDOBARRIER GASTROINTESTINAL LINER) FOR WEIGHT LOSS AND TREATMENT OF TYPE II DIABETES
    Patel, S.
    Hakim, D.
    Mason, J.
    Hakim, N.
    GUT, 2013, 62 : A159 - A159
  • [34] The Duodenal-Jejunal Bypass Sleeve (EndoBarrier Gastrointestinal Liner) for Weight Loss and Treatment of Type II Diabetes
    Shaneel R. Patel
    John Mason
    Nadey Hakim
    Indian Journal of Surgery, 2012, 74 : 275 - 277
  • [35] WEIGHT LOSS AND METABOLIC IMPROVEMENTS ONE YEAR AFTER TREATMENT WITH A DUODENAL-JEJUNAL BYPASS SLEEVE (ENDOBARRIER®)
    McMaster, Jessica J.
    Shanahan, Erin R.
    Anh Do
    Rich, Graeme
    Veronique, Chachay
    Macdonald, Graeme A.
    Holtmann, Gerald J.
    GASTROENTEROLOGY, 2019, 156 (06) : S1170 - S1171
  • [36] Comparison of Effects of Sleeve Gastrectomy, Duodenal-Jejunal Bypass and Ileal Transposition for the Treatment of Type II Diabetes
    Tong, Daniel K.
    Lai, Kenneth K.
    Chan, Kin-Tak
    Lee, Nikki P.
    Man, Kwan
    Law, Simon
    GASTROENTEROLOGY, 2014, 146 (05) : S1055 - S1055
  • [37] The Duodenal-Jejunal Bypass Sleeve (EndoBarrier Gastrointestinal Liner) for Weight Loss and Treatment of Type II Diabetes
    Patel, Shaneel R.
    Mason, John
    Hakim, Nadey
    INDIAN JOURNAL OF SURGERY, 2012, 74 (04) : 275 - 277
  • [38] Laparoscopic Sleeve Gastrectomy with Duodenal Jejunal Bypass
    Tagaya, N.
    Kanehira, E.
    Seki, Y.
    Kinouchi, M.
    Umezawa, A.
    Negishi, Y.
    Kurokawa, Y.
    OBESITY SURGERY, 2009, 19 (08) : 965 - 965
  • [39] DUODENAL-JEJUNAL BYPASS SLEEVE SYSTEM PLACEMENT: REPORT OF A SEVERE COMPLICATION LEADING TO LEFT LIVER LOBECTOMY
    Badiali, Sara
    Mozzi, Enrico
    Lauro, Roberto
    Paone, Gianni
    Chierici, Andrea
    Nencioni, Marco
    OBESITY SURGERY, 2015, 25 : S223 - S224
  • [40] The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes
    Patel, Shaneel R. H.
    Hakim, David
    Mason, John
    Hakim, Nadey
    SURGERY FOR OBESITY AND RELATED DISEASES, 2013, 9 (03) : 482 - 484